767.33
price up icon4.04%   29.77
after-market アフターアワーズ: 767.30 -0.03 -0.00%
loading
前日終値:
$737.56
開ける:
$775.92
24時間の取引高:
508.34K
Relative Volume:
1.25
時価総額:
$46.96B
収益:
$3.06B
当期純損益:
$1.28B
株価収益率:
39.01
EPS:
19.6719
ネットキャッシュフロー:
$447.35M
1週間 パフォーマンス:
+5.15%
1か月 パフォーマンス:
+7.74%
6か月 パフォーマンス:
+35.31%
1年 パフォーマンス:
+40.21%
1日の値動き範囲:
Value
$763.52
$786.20
1週間の範囲:
Value
$698.92
$786.20
52週間の値動き範囲:
Value
$510.06
$786.20

Argen X Se Adr Stock (ARGX) Company Profile

Name
名前
Argen X Se Adr
Name
セクター
Healthcare (1142)
Name
電話
-
Name
住所
-
Name
職員
1,639
Name
Twitter
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
ARGX's Discussions on Twitter

ARGX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ARGX
Argen X Se Adr
767.33 45.14B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
404.21 100.41B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
599.94 59.59B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
460.65 59.77B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ONC
Beone Medicines Ltd Adr
335.16 37.42B 4.56B -176.77M 225.30M -1.7177

Argen X Se Adr Stock (ARGX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-09-15 再開されました Truist Buy
2025-09-11 ダウングレード Deutsche Bank Buy → Hold
2025-08-25 開始されました RBC Capital Mkts Outperform
2025-07-08 アップグレード Deutsche Bank Hold → Buy
2025-07-03 再開されました Morgan Stanley Overweight
2025-05-13 アップグレード Robert W. Baird Neutral → Outperform
2025-03-17 アップグレード Bernstein Mkt Perform → Outperform
2025-03-12 アップグレード Deutsche Bank Sell → Hold
2025-01-17 ダウングレード Deutsche Bank Hold → Sell
2024-11-12 アップグレード Wolfe Research Peer Perform → Outperform
2024-11-05 アップグレード Scotiabank Sector Perform → Sector Outperform
2024-11-01 ダウングレード Robert W. Baird Outperform → Neutral
2024-11-01 アップグレード William Blair Mkt Perform → Outperform
2024-10-10 再開されました Raymond James Strong Buy
2024-10-04 ダウングレード Deutsche Bank Buy → Hold
2024-08-06 アップグレード Barclays Equal Weight → Overweight
2024-07-25 アップグレード Deutsche Bank Hold → Buy
2024-07-23 アップグレード Oppenheimer Perform → Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2023-12-20 ダウングレード Deutsche Bank Buy → Hold
2023-12-20 ダウングレード William Blair Outperform → Mkt Perform
2023-07-31 開始されました Scotiabank Sector Perform
2023-07-24 ダウングレード UBS Buy → Neutral
2023-07-17 再開されました Evercore ISI Outperform
2023-06-15 開始されました Societe Generale Sell
2023-05-31 開始されました UBS Buy
2023-04-25 開始されました Citigroup Buy
2023-03-14 アップグレード Robert W. Baird Neutral → Outperform
2022-12-07 開始されました William Blair Outperform
2022-10-12 開始されました Oppenheimer Perform
2022-07-29 ダウングレード Robert W. Baird Outperform → Neutral
2022-06-28 再開されました Stifel Buy
2022-05-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-12-08 開始されました Wells Fargo Overweight
2021-11-29 アップグレード Piper Sandler Neutral → Overweight
2021-10-29 アップグレード Guggenheim Neutral → Buy
2021-10-28 アップグレード Raymond James Outperform → Strong Buy
2021-10-07 開始されました Jefferies Buy
2021-09-23 アップグレード Redburn Neutral → Buy
2021-09-07 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-07-23 開始されました Deutsche Bank Hold
2021-07-19 再開されました Wolfe Research Outperform
2021-06-18 開始されました UBS Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-05-10 アップグレード H.C. Wainwright Neutral → Buy
2021-04-23 開始されました Redburn Neutral
2021-03-05 繰り返されました H.C. Wainwright Neutral
2021-02-02 ダウングレード Piper Sandler Overweight → Neutral
2021-01-04 ダウングレード Guggenheim Buy → Neutral
2020-08-25 開始されました Raymond James Outperform
2020-08-19 ダウングレード Evercore ISI Outperform → In-line
2020-07-29 開始されました H.C. Wainwright Neutral
2020-02-10 開始されました BofA/Merrill Buy
2019-11-05 開始されました Credit Suisse Neutral
2019-10-31 アップグレード William Blair Mkt Perform → Outperform
2019-10-22 開始されました JP Morgan Overweight
2019-09-27 開始されました Wells Fargo Market Perform
2019-09-16 再開されました Cowen Outperform
2019-06-28 開始されました Robert W. Baird Outperform
2019-01-18 再開されました SunTrust Buy
2019-01-04 開始されました Morgan Stanley Overweight
2018-12-17 開始されました Goldman Buy
2018-12-14 開始されました Wolfe Research Outperform
2018-06-29 開始されました Nomura Buy
2018-04-09 開始されました SunTrust Buy
2018-01-29 繰り返されました JMP Securities Mkt Outperform
すべてを表示

Argen X Se Adr (ARGX) 最新ニュース

pulisher
Oct 01, 2025

Argenx stock hits all-time high at 781.12 USD - Investing.com

Oct 01, 2025
pulisher
Sep 29, 2025

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today - Sahm

Sep 29, 2025
pulisher
Sep 18, 2025

Argenx Se (ARGX) Receives a Rating Update from a Top Analyst - The Globe and Mail

Sep 18, 2025
pulisher
Sep 16, 2025

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm

Sep 16, 2025
pulisher
Sep 16, 2025

Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail

Sep 16, 2025
pulisher
Sep 08, 2025

14 Newly Overvalued Stocks for the Week - Morningstar

Sep 08, 2025
pulisher
Sep 03, 2025

Argenx stock hits all-time high at 716.89 USD - Investing.com

Sep 03, 2025
pulisher
Aug 27, 2025

Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating - MSN

Aug 27, 2025
pulisher
Aug 26, 2025

Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded - Investor's Business Daily

Aug 26, 2025
pulisher
Aug 25, 2025

Argenx Tops Buy Point On Bullish Study, 850 Price Target - Investor's Business Daily

Aug 25, 2025
pulisher
Aug 25, 2025

Argenx stock reaches all-time high at 696.94 USD - Investing.com

Aug 25, 2025
pulisher
Aug 25, 2025

Argenx: study met primary endpoint - AInvest

Aug 25, 2025
pulisher
Aug 25, 2025

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - GlobeNewswire Inc.

Aug 25, 2025
pulisher
Aug 21, 2025

Argenx Shares Rise 0.42% with $190M Volume Ranking 464th Amid Biotech Sector Surge - AInvest

Aug 21, 2025
pulisher
Aug 21, 2025

European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest

Aug 21, 2025
pulisher
Aug 21, 2025

Earnings call transcript: Argenx Q2 2025 reports robust earnings beat - Investing.com

Aug 21, 2025
pulisher
Aug 19, 2025

Argenx's Growth Fuels Strong Demand for Vyvgart; Pipeline Continues to Develop - Morningstar

Aug 19, 2025
pulisher
Aug 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - GlobeNewswire Inc.

Aug 17, 2025
pulisher
Aug 15, 2025

This Stock Ran 31% In A Month. Will Upcoming News Revitalize It? - Investor's Business Daily

Aug 15, 2025
pulisher
Aug 08, 2025

argenx ADR Earns Relative Strength Rating Upgrade; Hits Key Benchmark - inkl

Aug 08, 2025
pulisher
Jul 31, 2025

Argenx NV ADR stock reaches all-time high at 689.13 USD By Investing.com - Investing.com South Africa

Jul 31, 2025
pulisher
Jul 31, 2025

Argenx NV ADR stock reaches all-time high at 689.13 USD - Investing.com Nigeria

Jul 31, 2025
pulisher
Jul 31, 2025

argenx ADR earnings beat by $3.26, revenue topped estimates - Investing.com South Africa

Jul 31, 2025
pulisher
Jul 21, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Jul 21, 2025
pulisher
Jul 03, 2025

Morgan Stanley assumes coverage on argenx stock with Overweight rating - Investing.com

Jul 03, 2025
pulisher
Jul 01, 2025

Argenx stock advances as H.C. Wainwright reiterates Buy rating - Investing.com

Jul 01, 2025
pulisher
Jun 30, 2025

Argenx stock falls after FDA flags serious risk signal with Vyvgart - Investing.com

Jun 30, 2025
pulisher
Jun 11, 2025

Argenx stock price target reiterated at $761 on positive trial data - Investing.com

Jun 11, 2025
pulisher
May 22, 2025

argenx SE’s SWOT analysis: biotech stock’s growth potential and challenges - Investing.com

May 22, 2025
pulisher
May 20, 2025

argenx ADR Shows Market Leadership With Jump To 84 RS Rating - Investor's Business Daily

May 20, 2025
pulisher
May 14, 2025

10 Stocks Analysts Are Upgrading Today - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

JMP cuts argenx stock target to $699, keeps outperform rating - Investing.com

May 14, 2025
pulisher
May 09, 2025

Argenx Earnings: Vyvgart Delivers Strong Sales Growth; Prefilled Syringe Expands Patient Access - Morningstar

May 09, 2025
pulisher
May 09, 2025

Metric Analysis: Argen X SE ADR (ARGX)’s Key Ratios in the Limelight - DWinneX

May 09, 2025
pulisher
May 09, 2025

Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX

May 09, 2025
pulisher
May 08, 2025

Biotech Tumbles. Why Its Sales Beat Wasn't Enough. - Investor's Business Daily

May 08, 2025
pulisher
May 08, 2025

argenx ADR earnings beat by $0.34, revenue topped estimates - Investing.com Nigeria

May 08, 2025
pulisher
May 08, 2025

Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga

May 08, 2025
pulisher
Apr 30, 2025

Argenx Stock Extends Rally In A Base As Earnings Loom - Investor's Business Daily

Apr 30, 2025
pulisher
Apr 14, 2025

argenx ADR Earns Relative Strength Rating Upgrade - inkl

Apr 14, 2025
pulisher
Apr 12, 2025

Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating By Investing.com - Investing.com South Africa

Apr 12, 2025
pulisher
Apr 11, 2025

Biotech Leader Surges On 'Best-Case Scenario' For Key Drug - Investor's Business Daily

Apr 11, 2025
pulisher
Apr 11, 2025

Guggenheim maintains Buy on Argenx stock, target at $1,100 - Investing.com India

Apr 11, 2025
pulisher
Apr 11, 2025

Guggenheim maintains Buy on Argenx stock, target at $1,100 By Investing.com - Investing.com South Africa

Apr 11, 2025
pulisher
Apr 11, 2025

Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating - Investing.com India

Apr 11, 2025
pulisher
Apr 11, 2025

Stifel maintains $780 target on argenx stock after FDA nod - Investing.com

Apr 11, 2025

Argen X Se Adr (ARGX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
biotechnology ONC
$335.16
price down icon 1.63%
$460.65
price up icon 1.02%
$599.94
price up icon 6.70%
$147.28
price up icon 2.27%
$102.21
price up icon 3.64%
大文字化:     |  ボリューム (24 時間):